MetaCap

Nurix Therapeutics Inc. Company Profile

NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

12.85-0.755 (-5.55%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Nurix Therapeutics at a glance

Nurix Therapeutics Inc. (NASDAQ: NRIX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Brisbane, CA. Nurix Therapeutics is led by Dr. Arthur T. Sands M.D., Ph.D. and employs about 317 people. The company's shares have traded publicly since 2020.

At a market capitalization of $1.40 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001549595, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Nurix Therapeutics do?

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Business description based on the company's public filings.

Company information

Legal name
Nurix Therapeutics Inc.
Ticker
NASDAQ: NRIX
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Arthur T. Sands M.D., Ph.D.
Employees
317
Headquarters
1600 Sierra Point Parkway, Brisbane, CA, United States
Phone
415 660 5320
IPO year
2020
SEC CIK
0001549595

Companies similar to Nurix Therapeutics

NRIX peer companies
CompanyPrice% ChgMarket capCompare
TYRATyra Biosciences Inc.20.12+1.98%$1.39Bvs NRIX
ANABAnaptysBio Inc.46.63-1.62%$1.39Bvs NRIX
ADRXADARx Pharmaceuticals Inc.12.79-9.68%$1.42Bvs NRIX
SRPTSarepta Therapeutics Inc.13.33-5.93%$1.43Bvs NRIX
KLRAKailera Therapeutics Inc.11.02-4.84%$1.43Bvs NRIX
RAPPRapport Therapeutics Inc.23.16-1.82%$1.37Bvs NRIX
DMRADamora Therapeutics Inc.23.22-4.44%$1.44Bvs NRIX
QUREuniQure N.V.19.35-4.35%$1.36Bvs NRIX

Related